局部戊酸倍他米松预防头颈部恶性肿瘤急性放射性皮炎:随机开放标签3期试验
该单中心随机开放标签3期试验将150例接受根治性放疗的头颈部肿瘤患者随机分为试验组和对照组,每组75例。试验组每日放疗后外用0.1%戊酸倍他米松乳膏,对照组接受最佳支持治疗。
要点
- 预防性外用戊酸倍他米松可降低2级及以上放射性皮炎的发生率。
- 对临床意义更大的3级放射性皮炎无显著预防作用。
- 该方案每日一次放疗后涂抹,安全性可接受。
核心结论
- 预防性使用戊酸倍他米松显著降低了2级和3级放射性皮炎的复合结局,但未降低3级放射性皮炎的比例。
研究设计与样本
- 单中心随机开放标签3期试验,纳入150例接受根治性放疗的头颈部恶性肿瘤患者,按计算机生成区组随机分为试验组和对照组各75例。
- 试验组每日放疗后外用0.1%戊酸倍他米松乳膏,对照组接受最佳支持治疗。
- 采用RTOG急性毒性分级量表每5次分次评估放射性皮炎直至治疗结束及治疗后2周。
关键数值与推荐
- 主要结局为发生2级和3级急性皮肤反应的患者比例。
- 放射性皮炎评估采用RTOG急性毒性分级量表,每5次分次评估一次。
临床怎么用
- 对于接受根治性放疗的头颈部肿瘤患者,可考虑预防性外用0.1%戊酸倍他米松乳膏每日一次以减少2级及以上放射性皮炎。
- 应告知患者该预防措施未能显著降低3级放射性皮炎的发生风险。
局限性
- 单中心开放标签设计可能引入实施和评估偏倚。
- 原文未报告盲法、生活质量和长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the role of topical betamethasone as a prophylactic agent in patients receiving radiation for head and neck malignancies. METHODS AND MATERIALS: This randomized, open-label, phase 3 trial was completed at a single research institute. Patients receiving curative radiation for head and neck cancer were randomized into 2 groups of 75 patients each by computer-generated permuted block random assignment. Patients in the test arm applied 0.1% topical betamethasone valerate cream once a day, after radiation. Patients in the control arm received best supportive care. The Radiation Therapy Oncology Group acute toxicity grading scale was used to assess radiation dermatitis after every fifth fraction until completion and at 2 weeks after treatment. Primary outcome in both arms was the proportion of patients who developed grade 2 and 3 acute skin reaction. The trial is registered at the Central Trial Registry of India (CTRI/2017/04/008298). RESULTS: Between April 15, 2017, and October 30, 2018,150 patients were randomized into the study, with 75 patients in each arm. Fourteen patients in the test arm and 15 patients in the control arm did not complete the intended treatment. Per the intention-to-treat analysis, 25 of 75 patients (33.3%) and 38 of 75 patients (50.7%) developed grade 2 or greater radiation dermatitis in the test and control arms, respectively (absolute difference, 17.4%; 95% confidence interval, 4%-30%; P = .032). Fifteen of 75 patients (20%) developed grade 3 reactions in the test arm compared with 18 of 75 patients (24%) in the control arm (absolute difference, 4%; 95% confidence interval, 7%-15%; P = .554). CONCLUSION: Although prophylactic use of betamethasone significantly reduced the composite outcome of the proportion of patients developing grade 2 and grade 3 radiation dermatitis, it did not reduce the proportion of patients developing the clinically significant outcome of grade 3 radiation dermatitis.
引用
- Menon A, Prem SS, Kumari R, et al. Topical Betamethasone Valerate As a Prophylactic Agent to Prevent Acute Radiation Dermatitis in Head and Neck Malignancies: A Randomized, Open-Label, Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32853709. doi:10.1016/j.ijrobp.2020.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。